Positive survival data from a randomized Phase II trial with PM1183 in platinum resistant ovarian cancer will be presented at ASCO

by Pharmamar Zeltia

​New clinical trial data from both Yondelis® and PM1183 have been selected by The American Society of Clinical Oncology (ASCO) for oral presentations

Read more

The pivotal and registrational trial of Yondelis® in Japan has been positive

by Pharmamar Zeltia

PharmaMar, a biotechnology subsidiary of Grupo Zeltia — MC:ZEL) has announced that its partner for Japan, Taiho Pharmaceutical Co., LTD., has communicated that the pivotal and registrational study o...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Palobiofarma announces the completion th...

by Palobiofarma

Palobiofarma S.L. is pleased to announce the “last patient last visi...

Photos Stream